Company: PACB
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001299130-25-000102
Chunk: 4

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part II, Item 1
Chunk 4
---
 adversely affect our business, operations, and financial results. Such risks are discussed more fully below and include, but are not limited to, risks related to:

•our ability to successfully market, commercialize, and sell current and future products and related maintenance services;

•our ability to achieve profitability for our business;

•our ability to implement required expense reduction initiatives;

•our ability to repay our debt and fund our long-term operations;

•our ability to successfully leverage and integrate our acquisitions and future acquisitions;

•our ability to successfully research, develop and timely manufacture our current and future products;

•management of new product introductions and transitions, resultant costs, and ability of new products to generate promised performance;

•recent significant changes to our leadership team and resultant disruptions to our business;

•retention, recruitment, and training of senior management, key personnel, scientists and engineers;

•our ability to further penetrate nucleic acid sequencing applications, as well as grow product demand;

•our reliance on outsourcing to other companies for manufacturing certain components and sub-assemblies, some of which are sole-sourced;

•the impact of tariffs recently imposed by the U.S. government and its trading partners in response, other possible tariffs or trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers;

•our ability to consistently manufacture our instruments and consumables to meet customers’ specifications, quantity, cost, or performance requirements;

•the high amount of competition we face in our industry;

•our ability to attract customers and increase sales of current and future products;

•our reliance on a limited number of customers for a significant portion of our revenues, including academic, research and government institutions, which may be impacted by reductions in funding or targeted cancellations of certain grants or contracts by the U.S. federal government;

•the complexity of our products giving rise to defects or errors;

•our unpredictable and lengthy sales cycles;

•the possibility that our goodwill or intangible assets could become impaired;

•adverse effects resulting from political and economic tensions between the United States and other countries, including China and Russia, and other geopolitical uncertainties;

•securing and maintaining patent or other intellectual property protection for our products and related improvements;

•current and future legal proceedings filed against us claiming intellectual property infringement;

Q1 Fiscal 2025 Form 10-Q41

•the potential adverse impact of health epidemics;

•potential cybersecurity incidents and security breaches;

•governmental regulations that burden operations or narrow the market for our products;

•